Videos

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical application of the data on HER2 gene amplification in patients with metastatic colorectal cancer, as well as the benefits of using a therapy that combines trastuzumab and pertuzumab.

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.

Heather Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses the evolving role of bevacizumab (Avastin) in the treatment of patients with non–small cell lung cancer.

Rose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses the many risk factors that can be associated with glioma.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.

Linda Bosserman, MD, medical oncologist, City of Hope, discusses the effects that payment reform may have on clinical practice in oncology.

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, compares mastectomy with breast conservation in the surgical management of breast cancer.

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the role of PARP inhibitors in castration-resistant prostate cancer.

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the relevance of sarcoma in the converging worlds of targeted therapies and immuno-oncology.

Richard M. Stone, MD, Program Director, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the CALGB 10603 trial, which explored the use of midostaurin as a treatment for patients with FLT3-mutated acute myeloid leukemia.